Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06631521 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
A Phase 1 study of Prostate Cancer (Adenocarcinoma) and Prostate CA, sponsored by AdventHealth.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06631521: Recruiting Phase 1 study of Prostate Cancer (Adenocarcinoma) and Prostate CA, sponsored by AdventHealth.
NCT06631521 is a Phase 1 study of Prostate Cancer (Adenocarcinoma) and Prostate CA that is actively recruiting participants, run by AdventHealth. The registered enrollment target is 30 participants, below the 128-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06631521, a Phase 1 study of Prostate Cancer (Adenocarcinoma) and Prostate CA, is actively recruiting participants, sponsored by AdventHealth.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in adult males.
Conditions Studied
Interventions
- DRUG Darolutamide
- DRUG Relugolix
- PROCEDURE Radical Prostatectomy
Study Locations (1)
Florida
- AdventHealth Orlando - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What NCT06631521 shows while recruiting
NCT06631521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 128-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 3 interventions - of which Darolutamide is the first listed.
NCT06631521 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06631521 about?
NCT06631521 is a clinical study titled "Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer". The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in adult males.
What is the current status of trial NCT06631521?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-10-22. Estimated completion is 2026-06.
What conditions does trial NCT06631521 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancer Surgery.
What interventions are being tested in trial NCT06631521?
The interventions under investigation include: Darolutamide (DRUG), Relugolix (DRUG), Radical Prostatectomy (PROCEDURE).
Who is sponsoring clinical trial NCT06631521?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06631521 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06631521's enrollment target sits among peer trials
30 13th of 13 higher than 1 of 13 other Prostate Cancer (Adenocarcinoma) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer (Adenocarcinoma) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
RECRUITING · Phase 1
-
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
PSMA PET for Surveillance After Focal Therapy
RECRUITING · NA
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI